pembrolizumab

Product

Anti-PD-1 checkpoint inhibitor immunotherapy drug marketed as Keytruda by Merck

4 stories

Personalized Cancer Vaccine Shows Sustained Survival Benefit Six Years After Treatment

Cancer Researchers Report Encouraging Early Results for mRNA Vaccine Therapies

New Wave of Cancer Immunotherapy Treatments Shows Dramatic Tumor Elimination Results

New Colorectal Cancer Treatment Achieves Complete Remission in Young Patient